Observed Signal · Oct 2, 2026 · Research Report · Source: PR Newswire: Technology News · Impact: 1/5 · Sentiment: Positive
Clinical Trial Supplies Market to Reach $8.95B by 2031
MarketsandMarkets forecasts the clinical trial supplies market to grow from USD 5.60 billion in 2026 to USD 8.95 billion by 2031, at a CAGR of 8.9%. The report highlights logistics and distribution as the largest service segment, small molecules as the dominant molecule type, and oncology as the leading therapeutic area. North America accounts for over 41.4% of global revenue. Key drivers include rising clinical trial numbers, increased R&D spending, and decentralized trial adoption. The report also details major M&A activity, including DHL's acquisition of CRYOPDP and UPS's acquisition of Andlauer Healthcare Group, reflecting consolidation in cold-chain logistics.
Market forecast report provides growth projections but is not directly about AdTech/MarTech or new technology announcements. Only tangentially relevant due to logistics tech integration.
Track MarketsandMarkets Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Market projected to grow from USD 5.60 billion in 2026 to USD 8.95 billion by 2031 at a CAGR of 8.9%.
- Logistics and distribution held the largest service segment share of 27.2% in 2025.
- North America accounted for over 41.4% of global revenue in 2025.
- DHL acquired CRYOPDP in March 2025.
- UPS completed acquisition of Andlauer Healthcare Group for approximately USD 1.6 billion in November 2025.
Connected Companies & Entities
3 Entities mapped“According to MarketsandMarkets™, the Clinical Trial Supplies Market is projected to reach USD 8.95 billion by 2031......”
“DHL acquired 100% of CRYOPDP from Cryoport....”
“UPS completed its acquisition of Andlauer Healthcare Group for approximately USD 1.6 billion....”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Diagnostic Imaging Market to Grow to $33.2B by 2031
A new Wissen Research report projects the global diagnostic imaging market to grow from $26.5 billion in 2026 to $33.2 billion by 2031, a 4.6% CAGR. Growth is driven by chronic disease prevalence, an aging population, and demand for early detection. Key trends include AI embedded directly into imaging acquisition (deep learning reconstruction), cloud-native PACS and teleradiology, photon-counting CT, and portable devices. However, reimbursement compression (e.g., CMS 2026 fee schedule adjustments) and high equipment costs pose challenges. Recent developments include GE HealthCare's SIGNA MRI launch, Siemens Healthineers' CT-guided intervention workflow, Samsung Medison's consolidation under HME America, and Fujifilm's ARIETTA Deep Insight x ultrasound platform.
Brands Use Clinical Research as Growth Engine
Supplement and cleaning brands like AG1, Ritual, and Blueland are increasingly funding their own clinical research to differentiate products, boost advertising performance, and gain retail shelf space. These companies conduct or commission studies published in peer-reviewed journals, using findings to support marketing claims and product development. For instance, AG1 committed $20 million to research, while Ritual has invested over $5 million in studies. Such research helps brands combat misinformation, appeal to data-driven consumers, and satisfy wholesale buyers demanding third-party validation. Although there is no official FTC definition of 'clinical,' companies follow guidelines requiring competent scientific evidence for health claims. This strategy serves as a long-term brand investment, with executives noting higher-performing ads and stronger retail positioning as outcomes.
Pharma advertisers adopt specialized ad tech
Pharmaceutical marketers are increasingly shifting ad dollars from traditional TV to digital channels and adopting specialized ad tech built for healthcare’s regulatory and privacy constraints. Industry data cited in the article forecasts healthcare and pharma digital ad spending at $26.2 billion versus $6.9 billion for traditional media, with social surpassing linear TV in 2025. Sources tell Digiday that niche vendors such as DeepIntent, Patient Point and Pulsepoint are winning share from legacy DSPs. DeepIntent, after a majority-stake sale to Vitruvian Partners for $637 million in late 2025, unveiled a healthcare-focused agentic AI product called Helix AI and new tools to buy premium live-streaming TV inventory, touting partnerships with major broadcasters and sports-rights holders. Agency and ad buyers say evolving FDA and state-level regulations are driving privacy‑forward targeting and measurement approaches.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.